key: cord-0935300-k2bl1fcz authors: Chau, Edward; Li, Shiqian; Xu, Peter Z.; Li, Grace X.; Ghasem, Wesley; Weitz, Ilene C.; DeClerck, Brittney K.; DePasquale, Eugene C.; Yaghmour, Bassam title: Acute ST-Segment Elevation Myocardial Infarction as Initial Presentation of Atypical Hemolytic-Uremic Syndrome date: 2021-03-03 journal: JACC Case Rep DOI: 10.1016/j.jaccas.2020.12.033 sha: a0341b90a1dcb0c166c0215dcccd717d2fa03b85 doc_id: 935300 cord_uid: k2bl1fcz A young woman presented with an acute ST-segment elevation myocardial infarction. Her clinical course was complicated by cardiogenic shock and acute renal failure. Work-up revealed thrombocytopenia and hemolytic anemia. A diagnosis of atypical hemolytic-uremic syndrome was made on the basis of clinical and pathological findings. (Level of Difficulty: Intermediate.) The patient arrived afebrile with sinus tachycardia at a heart rate of 107 beats/min while being ventilated with a fraction of inspired oxygen of 60%. She was noted to be obese and sedated, and she had crackles in the lung bases with 2รพ dependent edema in the arms and lower extremities. The initial complete blood count at our institution showed the following: white blood count, 21.37 10 3 /ml; hemoglobin, 7.3 g/dl; and platelet count, 120 fl ( Table 1 ). The platelets continued to downtrend to a nadir of 106 fl without Electrocardiogram showing right bundle branch block and ST-segment elevation in leads II, III, aVF, and V 3 to V 6 . The quality is poor because it is a scanned copy from an outside hospital. A P R I L 2 0 2 1 : 5 6 1 -5 concurrent Impella use. Given concern for heparininduced thrombocytopenia (HIT) with a 4T score of 6 (64% probability), she was switched from heparin to argatroban. Results of an HIT antibody screen were positive but, results of a serotonin releasing assay confirmatory testing were negative. Other relevant laboratory findings include the following ( Table 1) : Ddimer, 5,205 ng/ml (normal high,<249 ng/ml); Creactive protein, 41.0 mg/l (normal high, <4.9 mg/l); high-sensitivity C-reactive protein, 9.0 mg/l (normal high, <4.9 mg/l); ferritin, 221 ng/ml (normal high,<204 ng/ml); haptoglobin, <10 mg/dl; and total bilirubin, 1.2 mg/dl. There was still concern for COVID-19, but the result of the third test, performed using mini-bronchoalveolar lavage, was negative. A peripheral blood smear showed significantly We report a case of a young woman who presented A P R I L 2 0 2 1 : 5 6 1 -5 the drug was associated with greater improvements in estimated glomerular filtration rate, clinical outcomes, and health-related quality of life (7). The patient continues to make a meaningful recovery. She is taking aspirin and ticagrelor for her stent. Another echocardiogram showed a recovered ejection fraction of 50% to 55%. With continued eculizumab treatments, her hemoglobin is improving, platelets have normalized, and lactate dehydrogenase is decreasing. After 2 weeks of being dialysis dependent, she is now making a significant amount of urine with medical management. In a young adult, aHUS may manifest as a nonatherosclerotic cause of STEMI. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Intracoronary optical coherence tomography: current status and future directions Extra-renal manifestations of atypical hemolytic uremic syndrome in children Atypical hemolytic-uremic syndrome Cardiovascular complications in atypical haemolytic uraemic syndrome Atypical hemolytic uremic syndrome presenting as acute heart failure-a rare presentation: diagnosis supported by skin biopsy Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome KEY WORDS acute heart failure, autoimmune, cardiovascular disease, myocardial infarction APPENDIX For supplemental videos, please see the online version of this article.